Evidence map›Paper›PMID 20009919›Full record

ArticleAIDS (London, England)2010

Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.

Weerawat Manosuthi, David M Butler, Josué Pérez-Santiago, Art Fy Poon, Satish K Pillai, Sanjay R Mehta, Mary E Pacold, Douglas D Richman, Sergei Kosakovsky Pond, Davey M Smith

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Weerawat ManosuthiUniversity of California San Diego, La Jolla, California, USA. drweerawat@hotmail.com
David M Butler
Josué Pérez-Santiago
Art Fy Poon
Satish K Pillai
Sanjay R Mehta
Mary E Pacold
Douglas D Richman
Sergei Kosakovsky Pond
Davey M Smith
University of California, San Diego · USBamrasnaradura Infectious Diseases Institute · THUniversity of California, San Francisco · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jessica Lynette Montoya · 2001 to 2026
$50.4M
Transmission ProbabilityP01AI074621 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2008 to 2012
$23.1M
Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitU01AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BENSON, CONSTANCE ANN · 2007 to 2011
$19.3M
A Multi-Site Investigation into the Effect of HIV Clade on Neurocognitive ImpairmR01MH083552 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2008 to 2012
$3.3M
Biomathematical analysis of viral dynamics/evolutionR01AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 2001 to 2011
$3.2M
Modeling HIV Escape from Neutralizing Antibody ResponesR01AI057167 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FROST, SIMON DAVID WILLIAM · 2004 to 2008
$1.2M
Antiviral Role of APOBEC3 in HIV/HCV Coinfected PatientsK01DA024654 · NIDA · VITALANT · PI PILLAI, SATISH KUMAR · 2008 to 2012
$902k
Detection and Characterization of HIV-1 Intraclade Dual InfectionR21AI077304 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI SMITH, DAVID MITCHELL · 2008 to 2009
$381k
Biomathematical Analysis of Viral Dynamics and EvolutionR56AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POND, SERGEI L KOSAKOVSKY · 2012 to 2012
$365k
NIAID NIH HHS AI047745NIAID NIH HHS AI077304NIAID NIH HHS AI36214NIAID NIH HHS AI43638NIAID NIH HHS AI47745NIAID NIH HHS AI57167NIAID NIH HHS AI69432NIAID NIH HHS AI74621NIAID NIH HHS P01 AI074621NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R01 AI057167NIAID NIH HHS R21 AI047745NIAID NIH HHS R21 AI077304NIAID NIH HHS R56 AI047745NIAID NIH HHS U01 AI043638NIAID NIH HHS U01 AI069432NIAID NIH HHS UM1 AI069432NIDA NIH HHS K01 DA024654NIMH NIH HHS MH083552NIMH NIH HHS MH62512NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH083552
6 · The paper itself

Abstract

backgroundMost of our knowledge about how antiretrovirals and host immune responses influence the HIV-1 protease gene is derived from studies of subtype B virus. We investigated the effect of protease resistance-associated mutations (PRAMs) and population-based HLA haplotype frequencies on polymorphisms found in CRF01_AE pro.

methodsWe used all CRF01_AE protease sequences retrieved from the LANL database and obtained regional HLA frequencies from the dbMHC database. Polymorphisms and major PRAMs in the sequences were identified using the Stanford Resistance Database, and we performed phylogenetic and selection analyses using HyPhy. HLA binding affinities were estimated using the Immune Epitope Database and Analysis.

resultsOverall, 99% of CRF01_AE sequences had at least 1 polymorphism and 10% had at least 1 major PRAM. Three polymorphisms (L10 V, K20RMI and I62 V) were associated with the presence of a major PRAM (P < 0.05). Compared to the subtype B consensus, six additional polymorphisms (I13 V, E35D, M36I, R41K, H69K, L89M) were identified in the CRF01_AE consensus; all but L89M were located within epitopes recognized by HLA class I alleles. Of the predominant HLA haplotypes in the Asian regions of CRF01_AE origin, 80% were positively associated with the observed polymorphisms, and estimated HLA binding affinity was estimated to decrease 19-40 fold with the observed polymorphisms at positions 35, 36 and 41.

conclusionPolymorphisms in CRF01_AE protease gene were common, and polymorphisms at residues 10, 20 and 62 most likely represent selection by use of protease inhibitors, whereas R41K and H69K were more likely attributable to recognition of epitopes by the HLA haplotypes of the host population.

Indexed as

Polymorphism, GeneticAmino Acid SequenceAnti-Retroviral AgentsAsian PeopleDrug Resistance, ViralHIV-1HIV InfectionsHIV ProteaseHumansMutationAnti-Retroviral AgentsHIV Protease

Identifiers

PMID20009919
PMCPMC2913588
OpenAlexW1980595240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.